BNP Paribas Exane downgraded Hologic (HOLX) to Neutral from Outperform with a $79 price target
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOLX:
- Hologic’s Financial Health at Risk: Navigating Reimbursement and Guideline Challenges
- Hologic price target raised to $76 from $69 at Morgan Stanley
- Hologic Updates Restricted Stock Unit Award Agreement
- Cautious Hold Rating for Hologic Amid Strong Q4 Results and Future Uncertainties
- Hologic’s Mixed Performance and Acquisition Uncertainty Lead to Hold Rating